Cardiovascular & Hematological Disorders-Drug Targets

(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Garry X. Shen  
University of Manitoba
Winnipeg, MB


Atrial Fibrillation – New Frontiers in Anticoagulation

Author(s): Ranji Thomas, Pierre Le Page and Andrew R.J. Mitchell

Affiliation: Department of Cardiology, Jersey General Hospital, Gloucester Street, St Helier, Jersey, JE1 3QS.

Keywords: Atrial fibrillation, apixaban, dabigatran, direct thrombin inhibitors, edoxaban, factor Xa, thromboembolism, warfarin, rivoroxaban.


Stroke is the most feared complication of atrial fibrillation but for over fifty years there has been no simple, effective preventative alternative to warfarin. The development of new risk algorithms such as CHADSVASC has resulted in more patients being recommended anticoagulation therapy. Fixed dose oral anticoagulation is a landmark in drug development for atrial fibrillation. The differences between the drugs are discussed and the trial data examined. As we enter this new frontier of therapy, there is no doubt that these drugs will transform the delivery of anticoagulation for patients with atrial fibrillation.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [45 - 49]
Pages: 5
DOI: 10.2174/1871529X1401140724094846